Juncture Wealth Strategies LLC Grows Stock Position in AbbVie Inc. $ABBV

Juncture Wealth Strategies LLC boosted its stake in shares of AbbVie Inc. (NYSE:ABBV) by 451.0% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 9,559 shares of the company’s stock after acquiring an additional 7,824 shares during the quarter. Juncture Wealth Strategies LLC’s holdings in AbbVie were worth $2,500,000 as of its most recent SEC filing.

A number of other institutional investors also recently modified their holdings of ABBV. Burk Holdings LLC acquired a new stake in AbbVie in the second quarter worth about $30,000. Marquette Asset Management LLC lifted its position in AbbVie by 52.2% during the 2nd quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares during the period. Abound Financial LLC acquired a new position in AbbVie in the fourth quarter valued at approximately $32,000. Principia Wealth Advisory LLC lifted its holdings in AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after buying an additional 44 shares during the period. Finally, Merkkuri Wealth Advisors LLC bought a new position in AbbVie in the first quarter valued at approximately $34,000. 70.23% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently issued reports on ABBV. BMO Capital Markets boosted their target price on AbbVie from $258.00 to $300.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Royal Bank Of Canada lifted their price objective on shares of AbbVie from $260.00 to $280.00 and gave the stock an “outperform” rating in a research note on Friday, July 10th. Cantor Fitzgerald restated an “overweight” rating and set a $240.00 price objective (down from $250.00) on shares of AbbVie in a report on Wednesday, September 16th. Canaccord Genuity Group increased their target price on shares of AbbVie from $282.00 to $290.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. Finally, Piper Sandler lifted their price target on shares of AbbVie from $298.00 to $303.00 and gave the stock an “overweight” rating in a research report on Thursday, August 20th. One analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and six have given a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and a consensus price target of $273.82.

Insider Transactions at AbbVie

In other AbbVie news, EVP Nicholas Donoghoe sold 32,710 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares of the company’s stock, valued at $18,607,500. The trade was a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.06% of the stock is currently owned by insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Strong Phase 3 lymphoma results: AbbVie and Genmab reported that Epkinly (epcoritamab) combined with R-CHOP significantly improved progression-free survival in newly diagnosed diffuse large B-cell lymphoma. The combination reduced the risk of disease progression or death by 51% versus R-CHOP alone, potentially positioning Epkinly as a frontline treatment standard and creating a larger commercial opportunity. The companies plan to discuss the results with global regulators. AbbVie and Genmab Epkinly Phase 3 results
• Positive Sentiment: Analysts raise their outlook: Scotiabank lifted its ABBV price target from $280 to $320 and maintained a “sector outperform” rating. HSBC separately outlined a bullish case for a potential $315 target, citing AbbVie’s pipeline and growth prospects. Wall Street’s average recommendation remains equivalent to “Buy,” although analyst optimism is already reflected in the stock’s elevated valuation. Scotiabank raises AbbVie price target
• Positive Sentiment: Pipeline diversification: Coverage highlighted AbbVie’s newly approved Parkinson’s disease pill, described as the first FDA-approved selective D1/D5 therapy, adding another potential growth driver beyond immunology and oncology.
• Neutral Sentiment: Upcoming earnings catalyst: Investors are looking ahead to AbbVie’s third-quarter report, expected later this month. Results and management’s outlook will be important tests for the stock after its substantial rally.
• Negative Sentiment: Lower near-term EPS guidance: AbbVie incorporated $216 million of acquired in-process research and development and milestone expenses into its third-quarter outlook, reducing adjusted EPS guidance to $3.73–$3.77 from the prior range of $3.87–$3.91. Full-year adjusted EPS guidance was also reduced by $0.11 to $13.76–$13.96, creating a modest earnings headwind. AbbVie updates 2026 EPS guidance
• Negative Sentiment: Pricing uncertainty: AbbVie’s participation in a federal 340B rebate pilot ahead of 2027, together with an anticipated Medicare price reduction for Vraylar, could pressure future pricing and margins, though the near-term financial impact remains uncertain.

AbbVie Price Performance

AbbVie stock traded up $0.89 during mid-day trading on Tuesday, hitting $266.65. 4,500,600 shares of the company’s stock traded hands, compared to its average volume of 6,436,153. The firm has a 50 day simple moving average of $258.05 and a two-hundred day simple moving average of $235.01. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $269.39. The stock has a market cap of $471.11 billion, a price-to-earnings ratio of 75.32, a P/E/G ratio of 1.19 and a beta of 0.24.

AbbVie (NYSE:ABBV) last posted its earnings results on Friday, July 31st. The company reported $3.65 earnings per share for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The company had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same quarter last year, the firm earned $2.97 earnings per share. The company’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts anticipate that AbbVie Inc. will post 14.05 earnings per share for the current fiscal year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a dividend of $1.73 per share. The ex-dividend date is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.6%. AbbVie’s payout ratio is currently 195.48%.

AbbVie Profile

AbbVie Inc is a global biopharmaceutical company that develops, manufactures and markets medicines for a range of serious and chronic health conditions. Its portfolio spans immunology, oncology, neuroscience, eye care, aesthetics, gastroenterology and women’s health.

The company’s products include the immunology medicines Skyrizi and Rinvoq; neuroscience treatments such as Vraylar, Ubrelvy and Qulipta; and oncology medicines including Imbruvica and Venclexta. AbbVie also markets Botox Cosmetic and Botox Therapeutic, as well as other products for aesthetics, eye care and specialty care.

AbbVie was established in 2013 as an independent, publicly traded company following its separation from Abbott Laboratories.